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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Aldosterone, a neurohormone known to affect electrolytes, has recently been 
implicated as playing a major role in the progression of heart failure, particularly in patients 
with systolic dysfunction. Major clinical trials designed to analyze clinical outcomes using an 
aldosterone antagonist have been done in two groups with heart failure. The ﬁ  rst was the Ran-
domized Aldactone Evaluation Study, which was done in symptomatic chronic advanced heart 
failure patients and showed that an aldosterone antagonist, spironolactone, reduced mortality 
signiﬁ  cantly compared with placebo. Very few of these patients were on standard therapy with 
beta blockade. Another study, the Eplerenone Post myocardial infarction Heart failure Efﬁ  cacy 
and SUrvival Study (EPHESUS), done in post-myocardial infarction patients with heart failure, 
demonstrated a signiﬁ  cant reduction in mortality and hospitalizations for patients randomized 
to the aldosterone antagonist eplerenone. These trial results provide the background for aldo-
sterone antagonist therapy in chronic advanced heart failure patients as well as post-myocardial 
infarction heart failure patients with reduced ejection.
Keywords: aldosterone, eplerenone, heart failure
Aldosterone has been known for about 50 years as a neurohormone that has a sig-
niﬁ  cant impact on metabolism. More recently aldosterone has been implicated as 
possibly playing a role in the progression of heart failure, particularly in patients with 
systolic dysfunction. This review will highlight the role of the aldosterone antagonist 
eplerenone in patients with heart failure.
Pathophysiology of heart failure
Heart failure is a complex syndrome with one million hospitalizations annually in 
the US. It is estimated that 5 million Americans have a diagnosis of heart failure, 
with the numbers increasing mostly in the elderly. The cost of caring for heart failure 
is approximately US$30 billion per year. Heart failure is the result of ventricular 
remodeling, changes in size, shape, structure, and function of the left ventricle that 
can be triggered by myocardial ischemia and/or myocardial infarction usually in the 
presence of vascular risk factors, or can become manifested in a more prolonged latent 
phase in patients with hypertension who develop ventricular hypertrophy. Pathways 
in ischemic, hypertensive/hypertrophic, or idiopathic cardiomyopathy can lead to 
systolic or diastolic dysfunction with eventual signs and symptoms of heart failure. 
Current understanding of the pathophysiology of heart failure involves the activation 
of a number of neurohormonal systems in response to some form of cardiac injury.
The predominant systems that become upregulated include the renin angiotensin 
aldosterone system (RAAS), the sympathetic nervous system, and the arginine vaso-
pressin system. Neurohormones expressed from activation of these systems play a sig-
niﬁ  cant role in the development and progression of heart failure. These neurohormones 
can have a direct impact on the ventricular remodeling process by several mechanisms 
including ischemia, apoptosis, and alteration of gene expression. Additionally, some Vascular Health and Risk Management 2006:2(4) 465–475
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neurohormones (norepinephrine) can have direct toxic effects 
on myocytes. Thus the contemporary treatment of heart 
failure, speciﬁ  cally in patients with systolic dysfunction, 
involves intensively antagonizing these neurohormonal sys-
tems. (Eichhorn and Bristow 1996). Speciﬁ  c agents that target 
the RAAS are angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers, and aldosterone antagonists. 
Agents that impact the sympathetic nervous system are the 
beta blockers.
The renin angiotensin aldosterone 
system
Physicians have known about the RAAS for some time. The 
system is active both at the tissue level as well as systemi-
cally. The rate-limiting enzyme in the activation of this sys-
tem is renin which acts to cleave a peptide, angiotensinogen, 
which is secreted from the liver, into an inactive substance 
angiotensin 1. This protein is subsequently acted upon by a 
ubiquitous enzyme, angiotensin converting enzyme (ACE), 
which converts angiogtension 1 to the active neurohormone 
angiotensin II. Additionally, ACE plays an important role 
in the breakdown of bradykinin. Angiotensin II mediates a 
number of adverse parameters that have a negative impact 
on ventricular function and also result in the augmentation 
of the remodeling process. In order for angiotensin II to exert 
these effects there must be interaction with an angiotensin 
receptor.
These receptors have recently been identiﬁ  ed and most of 
our information relates to the AT1 receptor which mediates 
vascular smooth muscle constriction, abnormal cell growth, 
and the release of aldosterone. In addition to its electrolyte 
and metabolic effects including sodium retention, water 
retention, potassium excretion, and magnesium excretion, 
aldosterone appears to play a very important role in the patho-
physiology of heart failure (Figure 1). Aldosterone promotes 
the development of myocardial ﬁ  brosis which can facilitate 
the remodeling process and lead to the progression of heart 
failure as well as the progression of symptoms. Addition-
ally, aldosterone decreases norepinephrine uptake and has 
a negative effect on endothelial function and increases PAI 
1 levels which can lead to an increase in thrombosis. This 
can promote ischemic events which can lead to arrhythmias, 
some of which can result in sudden cardiac death which is 
frequently seen in patients with heart failure, particularly 
those with systolic dysfunction.
It was thought that pharmacologic therapy directed at 
decreasing neurohormonal activation by impacting the RAAS 
would have an effect on aldosterone. However, treatment  Figure 1 Pathophysiology of aldosteronone in heart failure.
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Aldosterone antagonism in heart failure
with either an ACE inhibitor alone or with an angiotensin 
receptor blocker alone or the two classes of agents combined 
does not decrease aldosterone levels (McKelvie et al 1999). 
A direct correlation of aldosterone levels and mortality 
was shown in the CONSENSUS trial. None of the patients 
enrolled in this trial received an aldosterone antagonist and 
elevation in aldosterone levels correlated with mortality 
(Swedberg et al 1990).
Clinical trial data
The ﬁ  rst study that indicated a potential role of an aldo-
sterone antagonist in patients with systolic heart failure 
was from the RALES or Randomized Aldactone Evalua-
tion study (Pitt et al 1999). In this trial 1663 patients with 
advanced heart failure and an ejection fraction below 35%, 
all of whom were on an ACE inhibitor and loop diuretic, 
were randomized to receive the non-selective aldosterone 
antagonist spironolactone at 25 mg per day vs placebo. 
The primary endpoint for this trial was total mortality. 
The majority of the patients in this study had a diagnosis 
of advanced heart failure, that is New York Heart Associa-
tion (NYHA) Class III or IV. Mean ejection fraction in 
this trial was 25%. Patients had ischemic (55%) or non-
ischemic (45%) etiology and were treated appropriately. It 
should be noted that this study was implemented prior to 
beta blockers becoming standard therapy for these types of 
patients. Only 10% of the patients in this trial were also on 
a beta blocker. Mortality was signiﬁ  cantly affected by the 
addition of spironolactone with a relative risk reduction of 
30%, which was highly statistically signiﬁ  cant and resulted 
in early termination of the trial. Serious hyperkalemia was 
a major disadvantage, with a relatively large number of 
hospitalizations and deaths from hyperkalemia following 
publication of the trial (Juurlink et al 2004). Additionally, 
a variety of side effects commonly seen with non-selective 
aldosterone antagonism were noted.
A compound with a similar structure to spironolactone 
but with more mineralocorticoid speciﬁ  city and conse-
quently fewer anti-androgenic and progestational actions is 
eplerenone. This aldosterone antagonist was approved for 
hypertension but had not been available for clinical practice. 
Because of the positive data available from small trials that 
noted the impact of ﬁ  brosis in the remodeling process of the 
left ventricle particularly following a myocardial infarction, 
it was hypothesized that giving post-infarction patients with 
heart failure an agent that seemed to decrease the amount of 
myocardial ﬁ  brosis might prove to be beneﬁ  cial regarding 
clinical outcomes.
Each year more 1 million Americans suffer a myocardial 
infarction. Of these individuals approximately 40% exhibit 
left ventricular systolic dysfunction. Many of these patients 
remain asymptomatic; however 22% of men and 46% of 
women who have experienced a myocardial infarction will 
be disabled with heart failure within 6 years.
Standard therapy for patients who have suffered a myo-
cardial infarction and who have developed clinical heart 
failure or who manifest left ventricular systolic dysfunction 
has been treatment with beta blockers and ACE inhibitors. 
Despite this therapy, mortality and morbidity remains high 
in these patients. Additionally, patients who have had a 
myocardial infarction tend to undergo a remodeling process 
relatively early following their infarction. With this back-
ground a new trial was designed using eplerenone as an 
intervention in patients post-myocardial infarction in order 
to reduce mortality and morbidity following a myocardial 
infarction with systolic left ventricular dysfunction. This 
trial, the Eplerenone Post myocardial infarction Heart failure 
Efﬁ  cacy and SUrvival Study (EPHESUS), randomized 6632 
post-myocardial infarction patients with ejection fractions 
below 40% and signs and symptoms of heart failure to either 
eplerenone at a dose of 25–50 mg daily vs placebo (Pitt 
et al 2003). All patients were treated with standard therapy 
including ACE inhibitors and beta blockers. The primary 
endpoint for this trial was total mortality and cardiovascular 
mortality or cardiovascular hospitalization. Secondary end-
points included cardiovascular mortality and total mortality 
or total hospitalizations. A cardiovascular hospitalization 
was deﬁ  ned as a hospitalization for myocardial infarction, 
stroke, heart failure, or a ventricular arrhythmia. The study 
was designed to continue until there were 1012 deaths. 
Events were adjudicated by a blinded endpoint adjudication 
committee and the trial was periodically reviewed by a data 
safety monitoring board.
Baseline characteristics of patients in this trial were 
somewhat different from patients in chronic heart failure 
trials in that ejection fraction (mean value 33%) was higher 
and many patients were relatively asymptomatic during the 
3- to 14-day window for starting the study drug. The patients 
were very well treated, with 86% of the study cohort being 
assigned to an ACE inhibitor or an angiotensin receptor 
blocker. Three quarters of the patients were on beta blockade, 
60% on diuretics. Forty-ﬁ  ve percent of the patients underwent 
some form of revascularization that included thrombolytic 
therapy, percutaneous coronary angioplasty, or coronary 
artery bypass graft surgery. The results of the study showed a 
small decrease in systolic and diastolic blood pressure at the Vascular Health and Risk Management 2006:2(4) 465–475
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end of the trial. Slight but signiﬁ  cantly higher serum potas-
sium and serum creatinine were also noted. Mortality was 
reduced, with a relative risk reduction of 15% (p = 0.008). 
Separation of the Kaplan Meier curves began at 3 months 
from randomization. The relative risk of cardiovascular mor-
tality and/or hospitalization was also signiﬁ  cantly improved 
in the eplerenone-assigned patients, by 13% (p = 0.002). 
Again the Kaplan Meier curves showed separation at 3 
months and continued to separate during the study. A very 
important secondary endpoint analyzed sudden cardiac death 
in this group of patients. This has been a difﬁ  cult area to treat 
in the post-infarction patient. However, in EPHESUS a rela-
tive risk reduction of sudden cardiac death of 21% was noted 
favoring the eplerenone-assigned group (p = 0.009). Hospi-
talizations for heart failure were also signiﬁ  cantly reduced 
during the trial. A post hoc analysis looking at 30-day events 
again favored assignment to eplerenone, with an all cause 
mortality reduction of 31% and a cardiovascular mortality 
reduction of 32% (Pitt et al 2005). Sudden cardiac death 
was reduced 37% during this time frame. In analyzing the 
patients with ejection fractions below 30%, all-cause mortal-
ity was reduced by 43% and sudden cardiac death by 50% at 
30 days. The mechanisms and beneﬁ  t of these outcomes in 
post-myocardial infarction patients may relate to attenuation 
or reversal of the remodeling process which can occur very 
rapidly post myocardial infarction. Myocardial ﬁ  brosis has 
been suggested to play a major role in the development of the 
remodeling process in the post-infarction patient. The stimu-
lus for this increased ﬁ  brosis is an increase in aldosterone. 
By selectively antagonizing aldosterone, the remodeling 
process is most likely attenuated or reversed, thereby lead-
ing to a reduction in cardiovascular events. Adverse events 
in the EPHESUS trial were quite small, with similarities to 
placebo. Potassium was relatively stable during the trial with 
a 1.6% absolute increase in serious hyperkalemia deﬁ  ned as 
potassium greater than 6.0 meq/L. Importantly, hypokalemia 
was prevented with this strategy.
Recommendations for monitoring serum potassium with 
aldosterone antagonists include obtaining a serum potassium 
level at 1 week and 1 month after initiating therapy and then 
obtain a potassium level at each visit. If potassium is less 
than 5 mmol/L at 1 month, uptitration will be performed. If 
potassium is 5.0–5.4 mmol/L, the dose will be maintained; 
if the level is 5.5–6.0 mmol/L, the dose will be decreased; 
and if the level is greater than 6.0 mmol/L, the drug will be 
discontinued.
It should be recognized that eplerenone and spironolactone 
manifest certain pharmacologic differences. Spironolactone 
is metabolized with a high degree of ﬁ  rst-pass metabolism 
and its half-life for metabolites is over 16 hours. Additionally, 
it is highly protein bound (Overdich and Merkus 1987). It is 
affected by the presence of food. Eplerenone, on the other 
hand, does not undergo ﬁ  rst-pass metabolism, has a shorter 
half life of 4–6 hours, does not possess active metabolites, 
is less than 50% protein bound, and is not affected by food 
intake. Drug interactions with statins and digoxin are not 
noted with eplerenone. Another major difference between 
spironolactone and eplerenone is cost. Since spironolactone 
is generic, the estimated cost of eplerenone is substantial. 
However, a recent study evaluated the cost beneﬁ  t related 
to survival following a myocardial infarction complicated 
by heart failure. This study showed that compared with 
placebo, eplerenone was cost effective in increasing years 
of life (Weintraub et al 2005). The incidence of gyneoco-
mastia (9% of men treated with spironolactone) is lower with 
eplereonone (<1%), attributed to its higher afﬁ  nity for the 
mineralocorticoid receptor.
Summary
Aldosterone appears to play a pivotal role in congestive heart 
failure. Important effects of this neurohormone include elec-
trolyte and ﬂ  uid shifts including potassium and magnesium 
loss and well as sodium retention. The neurohormone potenti-
ates catecholamines and can promote ventricular arrhythmias. 
Prothrombotic effects are well known with aldosterone, 
and cellular effects on endothelial dysfunction and vascular 
inﬂ  ammation and injury have also been noted. Perhaps one 
of the most important aspects of this neurohormone is its 
ability to increase myocardial ﬁ  brosis. One of the primary 
roles of the aldosterone antagonist eplerenone is probably 
some attenuation of the stimulus for myocardial ﬁ  brosis thus 
resulting in improved outcomes (Pitt et al 1999).
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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